Bretylium (tosylate)

Bretylium (tosylate) is an inhibitor of the presynaptic release of vasoconstrictor neurotransmitters. It is the sympathetic nerve and adrenergic ganglion blocking agent . (1) Bretylium tosylate inhibits adrenergic function presynaptically only after an initial release in neurotransmitter substance. (2) The reference for administration dose is 15 mg/kg (I.P) .

Product Specifications

CAS Number

[61-75-6]

UNSPSC

12352005

Hazard Statement

H302+H312+H332

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Bretylium-tosylate.html

Concentration

10mM

Purity

99.90

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C[N+](C)(CC)CC1=CC=CC=C1Br.O=S(C2=CC=C(C)C=C2)([O-])=O

Molecular Formula

C18H24BrNO3S

Molecular Weight

414.36

Precautions

H302+H312+H332

References & Citations

[1]McGinn R et al. Adenosine receptor inhibition attenuates the suppression of postexercise cutaneous blood flow. J Physiol. 2014 Jun 15;592 (12) :2667-78.|[2]Tew GA et al. Aging and aerobic fitness affect the contribution of noradrenergic sympathetic nerves to the rapid cutaneous vasodilator response to local heating. J Appl Physiol (1985) . 2011 May;110 (5) :1264-70|[3]Cakir B et al.Leptin inhibits gastric emptying in rats: role of CCK receptors and vagal afferent fibers. Physiol Res. 2007;56 (3) :315-22. Epub 2006 Jun 22.